sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
|
lithium
|
angiotensin II receptor antagonists
|
MECHANISM
|
Candesartan_ddi.xml
|
DDI-DrugBank.d547.s2
|
DDI-DrugBank.d547.s2.p8
|
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
|
isocarboxazid
|
tranylcypromine
|
NONE
|
L-Tryptophan_ddi.xml
|
DDI-DrugBank.d63.s0
|
DDI-DrugBank.d63.s0.p18
|
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
|
sirolimus
|
diltiazem
|
MECHANISM
|
11180036.xml
|
DDI-MedLine.d86.s5
|
DDI-MedLine.d86.s5.p0
|
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
|
isosorbide dinitrate
|
protamine
|
NONE
|
Dobutamine_ddi.xml
|
DDI-DrugBank.d274.s3
|
DDI-DrugBank.d274.s3.p66
|
Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
|
Itraconazole
|
isoniazid
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s25
|
DDI-DrugBank.d165.s25.p2
|
Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
|
Cisapride
|
procainamide
|
ADVISE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s14
|
DDI-DrugBank.d237.s14.p2
|
Concomitant use of HIVID with didanosine is not recommended.
|
HIVID
|
didanosine
|
ADVISE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s14
|
DDI-DrugBank.d263.s14.p0
|
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
|
carbamazepine
|
topiramate
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s14
|
DDI-DrugBank.d212.s14.p5
|
Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
|
macrolides
|
warfarin
|
EFFECT
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s5
|
DDI-DrugBank.d53.s5.p0
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
tubocurarine
|
succinylcholine
|
NONE
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p6
|
Caution should be used when alosetron and ketoconazole are administered concomitantly.
|
alosetron
|
ketoconazole
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s9
|
DDI-DrugBank.d364.s9.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
amiodarone
|
phenytoin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p244
|
Therefore, use of lamivudine in combination with zalcitabine is not recommended
|
lamivudine
|
zalcitabine
|
ADVISE
|
Lamivudine_ddi.xml
|
DDI-DrugBank.d71.s6
|
DDI-DrugBank.d71.s6.p0
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
narcotics
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p1
|
Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively. A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
|
magnesium hydroxide
|
mefenamic acid
|
MECHANISM
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s14
|
DDI-DrugBank.d400.s14.p13
|
Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
|
LEXAPRO
|
lithium
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s12
|
DDI-DrugBank.d568.s12.p5
|
Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
|
Iron
|
iron supplement
|
NONE
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s5
|
DDI-DrugBank.d420.s5.p7
|
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3).
|
insulin
|
NaCMC
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s9
|
DDI-MedLine.d76.s9.p3
|
After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.
|
Fluvoxamine
|
MAOI
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s5
|
DDI-DrugBank.d76.s5.p0
|
- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.
|
immuno-suppressant
|
bezafibrate
|
EFFECT
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s6
|
DDI-DrugBank.d291.s6.p0
|
The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
|
diltiazem
|
fentanyl
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s3
|
DDI-DrugBank.d170.s3.p1
|
Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
|
carbamazepine
|
SUPRAX
|
MECHANISM
|
Cefixime_ddi.xml
|
DDI-DrugBank.d339.s0
|
DDI-DrugBank.d339.s0.p2
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
alcohol
|
dicumarol
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p25
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
aluminum
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p32
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
tamoxifen
|
warfarin
|
NONE
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p90
|
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
|
levobupivacaine
|
rifampin
|
MECHANISM
|
Levobupivacaine_ddi.xml
|
DDI-DrugBank.d320.s3
|
DDI-DrugBank.d320.s3.p2
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
narcotic
|
codeine
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p99
|
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
|
aspirin
|
Nalfon
|
NONE
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s2
|
DDI-DrugBank.d154.s2.p7
|
There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
|
Desyrel
|
buspirone HCl
|
EFFECT
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s1
|
DDI-DrugBank.d463.s1.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
desipramine
|
topiramate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p499
|
Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
|
ketoconazole
|
aliskiren
|
MECHANISM
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s4
|
DDI-DrugBank.d533.s4.p3
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
methylphenidate
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p13
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
MAOIs
|
sertraline
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p13
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
tacrolimus
|
valproate
|
NONE
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p43
|
When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
|
warfarin
|
nevirapine
|
ADVISE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s11
|
DDI-DrugBank.d270.s11.p0
|
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
|
Contraceptive
|
ethinyl estradiol
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s33
|
DDI-DrugBank.d438.s33.p1
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
|
thiazides
|
nicotinic acid
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s4
|
DDI-DrugBank.d245.s4.p6
|
Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
|
Cyclopentolate
|
pilocarpine
|
EFFECT
|
Cyclopentolate_ddi.xml
|
DDI-DrugBank.d298.s0
|
DDI-DrugBank.d298.s0.p1
|
Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
|
lithium
|
Hydrochlorothiazide
|
ADVISE
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s11
|
DDI-DrugBank.d162.s11.p0
|
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.
|
VIRACEPT
|
sulfamethoxazole
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s5
|
DDI-DrugBank.d340.s5.p2
|
Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
|
Amphetamines
|
norepinephrine
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s18
|
DDI-DrugBank.d158.s18.p2
|
Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
|
ammonium chloride
|
amphetamine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s1
|
DDI-DrugBank.d236.s1.p4
|
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
|
hormonal contraceptives
|
alprazolam
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s17
|
DDI-DrugBank.d485.s17.p9
|
Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
|
diclofenac
|
NSAIDs
|
ADVISE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s1
|
DDI-DrugBank.d249.s1.p4
|
Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
|
Panretin
|
N-diethyl-m-toluamide
|
ADVISE
|
Alitretinoin_ddi.xml
|
DDI-DrugBank.d392.s0
|
DDI-DrugBank.d392.s0.p1
|
The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
|
sodium cephalothin
|
Coly-Mycin M
|
ADVISE
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s4
|
DDI-DrugBank.d250.s4.p0
|
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
|
NSAIDs
|
methotrexate
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s7
|
DDI-DrugBank.d219.s7.p6
|
While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
|
phenytoin
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s14
|
DDI-DrugBank.d60.s14.p1
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
antiarrhythmic agents
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p6
|
May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).
|
phenothiazines
|
procainamide
|
NONE
|
Isoetharine_ddi.xml
|
DDI-DrugBank.d541.s0
|
DDI-DrugBank.d541.s0.p14
|
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
|
Bezalip retard
|
anion-exchange resins
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s9
|
DDI-DrugBank.d291.s9.p5
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
grepafloxacin
|
antihistamines
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p67
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
Monoamine oxidase inhibitors
|
Flupenthixol
|
NONE
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p16
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Kaletra
|
Kadian
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p874
|
Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
|
Rifampin
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s36
|
DDI-DrugBank.d485.s36.p5
|
therefore concomitant administration of Itraconazole with cisapride is contraindicated.
|
Itraconazole
|
cisapride
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s10
|
DDI-DrugBank.d165.s10.p0
|
However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
|
HMG-CoA reductase inhibitor
|
warfarin
|
EFFECT
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s14
|
DDI-DrugBank.d567.s14.p0
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
Antihistamines
|
alcohol
|
EFFECT
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p0
|
DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
|
DISULFIRAM
|
PHENYTOIN
|
ADVISE
|
Disulfiram_ddi.xml
|
DDI-DrugBank.d19.s1
|
DDI-DrugBank.d19.s1.p0
|
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
|
anticonvulsants
|
antituberculosis drug
|
NONE
|
Norethindrone_ddi.xml
|
DDI-DrugBank.d306.s0
|
DDI-DrugBank.d306.s0.p9
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
metronidazole
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p28
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
warfarin
|
alprazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p88
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
Acetazolamide
|
isoniazid
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p36
|
There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
|
fluphenazine
|
clonidine
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s8
|
DDI-DrugBank.d495.s8.p0
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
antidepressants
|
beta-blockers
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p26
|
Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.
|
Ethanol
|
Triazolam
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s20
|
DDI-DrugBank.d277.s20.p0
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
topiramate
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p26
|
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
monoamine oxidase (MAO) inhibitors
|
antihistamines
|
NONE
|
Buclizine_ddi.xml
|
DDI-DrugBank.d342.s0
|
DDI-DrugBank.d342.s0.p26
|
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
|
d-amphetamine
|
protriptyline
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s4
|
DDI-DrugBank.d158.s4.p1
|
The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
|
dopamine
|
Bretylium Tosylate
|
EFFECT
|
Bretylium_ddi.xml
|
DDI-DrugBank.d180.s1
|
DDI-DrugBank.d180.s1.p4
|
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
|
enalaprilat
|
diuretic
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s1
|
DDI-DrugBank.d107.s1.p4
|
In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
|
haloperidol
|
rifampin
|
MECHANISM
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s4
|
DDI-DrugBank.d186.s4.p0
|
MAO Inhibitors: DURAGESIC is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
|
MAO inhibitors
|
opioid analgesics
|
ADVISE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s7
|
DDI-DrugBank.d170.s7.p9
|
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
|
dopamine agonist
|
APOKYN
|
NONE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s3
|
DDI-DrugBank.d357.s3.p23
|
Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
|
digoxin
|
carvedilol
|
MECHANISM
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s11
|
DDI-DrugBank.d269.s11.p5
|
Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
|
caffeine
|
Clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s17
|
DDI-DrugBank.d480.s17.p4
|
Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
|
Itraconazole
|
digoxin
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s15
|
DDI-DrugBank.d165.s15.p2
|
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
|
VIRACEPT
|
rifabutin
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s7
|
DDI-DrugBank.d340.s7.p1
|
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
|
antihistamines
|
CNS depressants
|
EFFECT
|
Clemastine_ddi.xml
|
DDI-DrugBank.d309.s0
|
DDI-DrugBank.d309.s0.p0
|
This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.
|
VIOXX
|
ACE inhibitors
|
ADVISE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s2
|
DDI-DrugBank.d210.s2.p0
|
Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
|
contraceptives
|
alprazolam
|
MECHANISM
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s7
|
DDI-DrugBank.d131.s7.p0
|
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
|
barbiturates
|
contraceptives
|
EFFECT
|
Butabarbital_ddi.xml
|
DDI-DrugBank.d184.s0
|
DDI-DrugBank.d184.s0.p90
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
amiodarone
|
pimozide
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p63
|
Caution should be used when NSAIDs are administered concomitantly with methotrexate.
|
NSAIDs
|
methotrexate
|
ADVISE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s3
|
DDI-DrugBank.d400.s3.p0
|
Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
|
erythromycin
|
loratadine
|
MECHANISM
|
Loratadine_ddi.xml
|
DDI-DrugBank.d258.s4
|
DDI-DrugBank.d258.s4.p0
|
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
|
Magnesium
|
vitamin D
|
EFFECT
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s15
|
DDI-DrugBank.d404.s15.p4
|
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
|
Monoamine Oxidase Inhibitors
|
monoamine oxidase inhibitors
|
NONE
|
Formoterol_ddi.xml
|
DDI-DrugBank.d103.s3
|
DDI-DrugBank.d103.s3.p2
|
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
|
fentanyl
|
troleandomycin
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s2
|
DDI-DrugBank.d170.s2.p3
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
tranquilizers
|
antianxiety agents
|
NONE
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p20
|
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
|
cimetidine
|
propafenone
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s15
|
DDI-DrugBank.d238.s15.p3
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
Agonist/antagonist analgesics
|
Levo-Dromoran
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p14
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
halothane
|
phenothiazines
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p188
|
Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
|
Cerubidine
|
doxorubicin
|
ADVISE
|
Daunorubicin_ddi.xml
|
DDI-DrugBank.d69.s1
|
DDI-DrugBank.d69.s1.p0
|
After multiple dosing, interferon beta-1a (AVONEX 30 mcg IM once weekly) reduced TYSABRI clearance by approximately 30%.
|
AVONEX
|
TYSABRI
|
MECHANISM
|
Natalizumab_ddi.xml
|
DDI-DrugBank.d232.s0
|
DDI-DrugBank.d232.s0.p2
|
The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
|
codeine
|
psychotropics
|
EFFECT
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s0
|
DDI-DrugBank.d398.s0.p2
|
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.
|
valdecoxib
|
glyburide
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s32
|
DDI-DrugBank.d328.s32.p1
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
selegiline hydrochloride
|
paroxetine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p18
|
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
|
HYDROXYZINE
|
CENTRAL NERVOUS SYSTEM DEPRESSANTS
|
EFFECT
|
Hydroxyzine_ddi.xml
|
DDI-DrugBank.d308.s0
|
DDI-DrugBank.d308.s0.p0
|
Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
|
aspirin
|
nicotinic acid
|
MECHANISM
|
Niacin_ddi.xml
|
DDI-DrugBank.d542.s1
|
DDI-DrugBank.d542.s1.p2
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
glutethimide
|
haloperidol
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p222
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.